Abstract:BACKGROUND: Hepatitis B virus (HBV) is a hepatotropic, noncytopathic, DNA virus which can cause acute and chronic infection. Viral persistence is associated with a weak or absent specific immune responses to HBV, particularly the cellular immune response. Dendritic cells (DCs) are professional antigen-presenting cells with a unique T cell stimulatory aptitude that play a crucial role in the instruction of adaptive immune responses upon infection. An impaired function of DCs was suggested by recent studies to account for the T and B cell hyporesponsiveness in chronic HBV infection. This review summarizes recent insights into the recognition of HBV antigens by DCs. DATA SOURCES: Studies were identified by searching MEDLINE and/or PubMed for articles using the key words "hepatitis B virus (HBV)", "dendritic cells", "C-type lectins", "mannose receptor", "toll-like receptor", and "dendritic cell-specific intercellular-adhesion-molecule-3 grabbing nonintegrin (DC-SIGN)" up to December 2009. Additional papers were identified by a manual search of the references from the key articles. RESULTS: DCs play an important role in the progress of hepatitis B, especially in the recognition of HBV. There are three main ways of recognition of HBV antigens by DCs. First, HBV DNA can be recognized by DCs through toll-like receptor 9 (TLR9) which activates the NF-kappa B signal pathway and p38 MAPK to up-regulate the expression of interferon (IFN) regulatory factor 7 (IRF-7) in a manner independent of type I IFN signaling, resulting in secretion of type I IFN and inflammatory cytokines, and induction of DC maturation and the adaptive immune response. Second, HBc/HBeAg cannot be recognized by DCs, but DNA or ssRNA encapsulated within HBcAg can be internalized by DCs through TLRs. Third, HBsAg can be internalized by DCs through the mannose receptor, which lacks the ability to induce DC maturation without the assistance of DC-SIGN. Meanwhile, there is some cross-talk among the three mechanisms, which induces an effective anti-viral response or HBV persistence. CONCLUSIONS: On the basis of these recognition processes, methods have been used to enhance the efficacy of DC-based vaccine against HBV and have been useful in the clinical application of HBV vaccine therapy. But the interactions between HBV antigens/HBV DNA and DCs are not clear, and cross-talk between TLRs and various ligands makes HBV antigen recognition by DCs more complicated. More efforts should be made to define the mechanisms and develop effective vaccines and therapies. (Hepatobiliary Pancreat Dis Int 2010; 9:584-592)

Dendritic Cell-Based Vaccination with Lentiviral Vectors Encoding Ubiquitinated Hepatitis B Core Antigen Enhances Hepatitis B Virus-Specific Immune Responses in Vivo

Immune Response Against Hepatitis B Virus Induced by HBsAg Recombinant Adenovirus-Transduced Dendritic Cells in BALB/c Mice

Immunostimulatory activities of dendritic cells loaded with adenovirus vector carrying HBcAg/HBsAg.

Enhancement of CTLs induced by DCs loaded with ubiquitinated hepatitis B virus core antigen.

Lentiviral Vector Encoding Ubiquitinated Hepatitis B Core Antigen Induces Potent Cellular Immune Responses and Therapeutic Immunity in HBV Transgenic Mice

Immunization with Lentiviral Vector‑modified Dendritic Cells Encoding Ubiquitinated Hepatitis B Core Antigen Promotes Th1 Differentiation and Antiviral Immunity by Enhancing P38 MAPK and JNK Activation in HBV Transgenic Mice.

Ubiquitin-modified hepatitis B virus core antigen effectively facilitates antigen presentation and enhances cytotoxic T lymphocyte activity via the cytoplasmic transduction peptide in vitro.

An engineered novel lentivector specifically transducing dendritic cells and eliciting robust HBV-specific CTL response by upregulating autophagy in T cells.

An Engineered DC-Targeting Lentivector Induces Robust T Cell Responses and Inhibits HBV Replication in HBV Transgenic Mice Via Upregulating T Cell Autophagy.

Ubiquitin-Hepatitis B Core Antigen-Cytoplasmic Transduction Peptide Enhances Hbv-Specific Humoral and Ctl Immune Responses in Vivo

Vaccination with ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances the hepatitis B virus-specific cytotoxic T-lymphocyte immune response and inhibits hepatitis B virus replication in transgenic mice

Study on the Immune Response Induced by Hbcag Gene-Modified Dendritic Cells in Hepatitis B Virus Transgenic Mice

TBK-1 Enhances Humoral and Cellular Immune Responses in Mice Induced by DNA Vaccination of HBV Core Gene

Recognition of HBV antigens and HBV DNA by dendritic cells.

Ubiquitin Conjugation of Hepatitis B Virus Core Antigen DNA Vaccine Leads to Enhanced Cell-Mediated Immune Response in BALB/c Mice

Induction of Tc1 Response and Enhanced Cytotoxic T Lymphocyte Activity in Mice by Dendritic Cells Transduced with Adenovirus Expressing HBsAg

Therapeutic Potential of Dendritic Cell-Based Immunization Against HBV in Transgenic Mice

Hepatitis B virus core antigen epitopes presented by HLA-A2 single-chain trimers induce functional epitope-specific CD8<sup>+</sup>T-cell responses in HLA-A2·1/Kb transgenic mice

Hepatitis B Virus Core Antigen Epitopes Presented By Hla-A2 Single-Chain Trimers Induce Functional Epitope-Specific Cd8(+) T-Cell Responses In Hla-A2.1/Kb Transgenic Mice

Effect of ubiquitination hepatitis B virus core antigen on inducing dendritic cells autophagy to enhance specific cytotoxic T lymphocyte responses

HBcAg-pulsed Dendritic Cell Vaccine Induces Th1 Polarization and Production of Hepatitis B Virus-Specific Cytotoxic T Lymphocytes.